COMMUNIQUÉS West-GlobeNewswire
-
Spectral AI Names Vincent S. Capone as Chief Executive Officer
10/02/2026 -
NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence
10/02/2026 -
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
10/02/2026 -
IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.20 Per Share from $0.17 Per Share
10/02/2026 -
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
10/02/2026 -
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
10/02/2026 -
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
10/02/2026 -
VirtuAlly Among First in Nation to Deliver Specialized Virtual Nursing in Neonatal Intensive Care Setting
10/02/2026 -
Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
10/02/2026 -
FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University
10/02/2026 -
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
10/02/2026 -
Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™
10/02/2026 -
Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
10/02/2026 -
Fangzhou’s MaaS Platform Recognized as Industry Leader at Guangdong Digital Economy Conference
10/02/2026 -
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
10/02/2026 -
Yatiri Bio Accurately Predicts AML Drug Response in Blinded Study Using Foghorn’s FHD-286
10/02/2026 -
Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026
10/02/2026 -
Santhera Appoints Stifel as Corporate Finance Advisor
10/02/2026 -
Philips delivers full year 2025 with growth acceleration, strong margin expansion and solid cash flow; announces 2026-2028 targets at Capital Markets Day
10/02/2026
Pages